Results of PAC203: A Randomized Phase II Dose-Finding Study and Determination of the Recommended Dose of Pacritinib
Aaron T. Gerds1, Michael R. Savona2, Bart L. Scott3, et al.
1 Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, USA
2 Department of Medicine and Program in Cancer Biology, Vanderbilt University Medical Center, Nashville, TN, USA
3 Fred Hutchinson Cancer Center, Seattle, WA, USA
Program: Oral and Poster Abstracts Type: Oral Session: 634. Myeloproliferative Syndromes: Clinical: JAK Inhibitors and Combination Therapies Hematology Disease Topics & Pathways: Diseases, MPN, Myeloid Malignancies Monday, December 9, 2019: 10:30 AM W311EFGH, Level 3 (Orange County Convention Center) Authors: Aaron T. Gerds1, Michael R. Savona2, Bart L. Scott3, et al....